BR112013030820A2 - combinação farmacêutica sinergística para o tratamento de carcinoma de células escamosas de cabeça e pescoço - Google Patents

combinação farmacêutica sinergística para o tratamento de carcinoma de células escamosas de cabeça e pescoço

Info

Publication number
BR112013030820A2
BR112013030820A2 BR112013030820A BR112013030820A BR112013030820A2 BR 112013030820 A2 BR112013030820 A2 BR 112013030820A2 BR 112013030820 A BR112013030820 A BR 112013030820A BR 112013030820 A BR112013030820 A BR 112013030820A BR 112013030820 A2 BR112013030820 A2 BR 112013030820A2
Authority
BR
Brazil
Prior art keywords
head
treatment
cell carcinoma
squamous cell
pharmaceutical combination
Prior art date
Application number
BR112013030820A
Other languages
English (en)
Inventor
Arun Balakrishnan
Giridharan Periyasamy
Veena Agarwal
Original Assignee
Piramal Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Entpr Ltd filed Critical Piramal Entpr Ltd
Publication of BR112013030820A2 publication Critical patent/BR112013030820A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112013030820A 2011-05-31 2012-05-30 combinação farmacêutica sinergística para o tratamento de carcinoma de células escamosas de cabeça e pescoço BR112013030820A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161491569P 2011-05-31 2011-05-31
PCT/IB2012/052698 WO2012164497A1 (en) 2011-05-31 2012-05-30 A synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck

Publications (1)

Publication Number Publication Date
BR112013030820A2 true BR112013030820A2 (pt) 2016-12-06

Family

ID=46551791

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013030820A BR112013030820A2 (pt) 2011-05-31 2012-05-30 combinação farmacêutica sinergística para o tratamento de carcinoma de células escamosas de cabeça e pescoço

Country Status (16)

Country Link
US (4) US20140112918A1 (pt)
EP (1) EP2714031B1 (pt)
JP (1) JP2014515394A (pt)
KR (1) KR20140056190A (pt)
CN (1) CN103561734B (pt)
AR (1) AR086625A1 (pt)
AU (1) AU2012264246A1 (pt)
BR (1) BR112013030820A2 (pt)
CA (1) CA2837042C (pt)
DK (1) DK2714031T3 (pt)
ES (1) ES2682270T3 (pt)
IL (1) IL229601A0 (pt)
MX (1) MX358501B (pt)
RU (1) RU2013158914A (pt)
TW (1) TW201300105A (pt)
WO (1) WO2012164497A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201300105A (zh) * 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
TW202031253A (zh) * 2013-07-12 2020-09-01 印度商皮拉馬爾企業有限公司 治療黑色素瘤的藥物組合
DK3148532T3 (en) 2014-05-28 2021-04-26 Piramal Entpr Ltd Pharmaceutical Combination Comprising a CDK Inhibitor and a Thioredoxin Reductase Inhibitor for the Treatment of Cancer
WO2017172826A1 (en) * 2016-03-28 2017-10-05 Presage Biosciences, Inc. Pharmaceutical combinations for the treatment of cancer
RU2711308C1 (ru) * 2019-07-13 2020-01-16 Михаил Сергеевич Ольшанский Способ паллиативного лечения рецидивов плоскоклеточного рака головы и шеи
EP4353236A1 (en) * 2021-06-10 2024-04-17 OnQuality Pharmaceuticals China Ltd. Compound and method for treating chemotherapy-related gastrointestinal side effects

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (pt) 1986-04-11 1989-02-04 Hoechst India
US5116954A (en) 1988-04-06 1992-05-26 Lipha, Lyonnaise Industrielle Pharmaceutique Pharmaceutically useful flavonoic compounds containing at least one substituent on the benzopyranone ring moiety
USH1427H (en) 1988-04-06 1995-04-04 Briet; Phillipe Substituted flavonoid compounds, their salts, their manufacture and their use in combination with interleukin-2
US5284856A (en) 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5723313A (en) 1995-09-27 1998-03-03 St. Jude Children's Research Hospital ARF-p19, a novel regulator of the mammalian cell cycle
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
WO2001072745A1 (en) 2000-03-29 2001-10-04 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders
KR20080064908A (ko) 2000-06-28 2008-07-09 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
US7915301B2 (en) 2002-07-08 2011-03-29 Piramal Life Science Limited Inhibitors of cyclin dependent kinases and their use
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
US7884127B2 (en) * 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
US7271193B2 (en) 2002-07-08 2007-09-18 Nicholas Piramal India, Ltd. Inhibitors of cyclin-dependent kinases and their use
MXPA05004919A (es) 2002-11-06 2005-08-18 Cyclacel Ltd Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina.
GB0328180D0 (en) 2003-12-04 2004-01-07 Cyclacel Ltd Combination
BRPI0416870A (pt) 2003-12-08 2007-01-30 Univ Arizona composições anticáncer sinergìticas
JP2008533039A (ja) 2005-03-11 2008-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 抗アポトーシスＢｃｌ−２ファミリーメンバーのクロメン−４−オン阻害剤およびその使用
NZ574266A (en) 2006-06-21 2011-10-28 Piramal Life Sciences Ltd Enantiomerically pure flavone derivatives for the treatment of poliferative disorders and processes for their preparation
GB0706633D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd Combination
AU2007353129B2 (en) 2007-05-15 2014-02-20 Piramal Enterprises Limited A synergistic pharmaceutical combination for the treatment of cancer
WO2009014642A1 (en) * 2007-07-19 2009-01-29 Amgen Inc. Combination of a de novo purine biosynthesis inhibitor and a cyclin dependent kinase inhibitor for the treatment of cancer
TWI461194B (zh) * 2009-05-05 2014-11-21 Piramal Entpr Ltd 吡咯啶取代黃酮作為輻射致敏劑
CA2781300A1 (en) * 2009-11-20 2011-05-26 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
TW201300105A (zh) * 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物

Also Published As

Publication number Publication date
US20170157090A1 (en) 2017-06-08
RU2013158914A (ru) 2015-07-10
IL229601A0 (en) 2014-01-30
CA2837042A1 (en) 2012-12-06
MX2013014071A (es) 2014-05-28
CN103561734B (zh) 2017-07-11
JP2014515394A (ja) 2014-06-30
US10245251B2 (en) 2019-04-02
EP2714031A1 (en) 2014-04-09
US20210196680A1 (en) 2021-07-01
KR20140056190A (ko) 2014-05-09
CN103561734A (zh) 2014-02-05
TW201300105A (zh) 2013-01-01
CA2837042C (en) 2018-12-11
NZ619488A (en) 2015-09-25
AR086625A1 (es) 2014-01-08
WO2012164497A1 (en) 2012-12-06
US20140112918A1 (en) 2014-04-24
MX358501B (es) 2018-08-23
US20190167639A1 (en) 2019-06-06
DK2714031T3 (en) 2018-08-06
AU2012264246A1 (en) 2014-01-09
ES2682270T3 (es) 2018-09-19
US10980776B2 (en) 2021-04-20
EP2714031B1 (en) 2018-05-23

Similar Documents

Publication Publication Date Title
HRP20181364T1 (hr) Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci
BR112015003376A8 (pt) composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
EP2727473A4 (en) COMBINATION OF EFFICIENT SUBSTANCES WITH SYNERGISTIC EFFECTS OF MULTIPLE TARGETING AND USE THEREOF
BR112015002524A2 (pt) derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças.
BR112013033072A2 (pt) agente para indução de apoptose e composição farmacêutica
BR302012002887S1 (pt) Configuração aplicada em garrafa para cuidado pessoal
EP2750686A4 (en) MITOCHONDRIAL TARGETING AND THERAPEUTIC USE THEREOF
BR112015001712A2 (pt) uso de s-pindolol para o tratamento da caquexia e sarcopenia
ZA201404306B (en) Razor head and razor
IL237125A0 (en) Use of preparations containing niclosamide and/or its derivatives for the treatment of solid tumors
HK1209424A1 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury
EP2823823A4 (en) USE OF POLYPEPTIDES IN THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF RHEUMATOID ARTHRITIS
EP2718283A4 (en) INDAZOLE AND PYRROLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
BR112013030820A2 (pt) combinação farmacêutica sinergística para o tratamento de carcinoma de células escamosas de cabeça e pescoço
BR112014031512A2 (pt) composição cosmética e método para o tratamento cosmético.
BR112014004416A2 (pt) composições e métodos para o tratamento de doenças neurodegenerativas
HK1209639A1 (en) Gpbp-1 inhibition and its therapeutic use gpbp-1
IL246286A0 (en) A medical preparation for the prevention and treatment of advanced myopia.
PL2874600T3 (pl) Kompozycja farmaceutyczna do leczenia chrypki lub bólów gardła.
EP2982680A4 (en) PROTAMINE PEPTIDOMIMETIC AND PHARMACEUTICAL ACCEPTABLE SALTS, AND USE THEREOF
ZA201306442B (en) Chop gate and nozzle
IL245015A0 (en) Medicinal composition containing icotinib for topical treatment of the skin and its use
BR112014009421A2 (pt) combinação terapêutica e método para tratamento
EP3019164A4 (en) Use of n-acetylcysteine amide in the treatment of penetrating head injury
BR112013020025A2 (pt) derivados de aminoestatina para o tratamento de artrose

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]